SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD

被引:2
作者
Roman, Iulia [1 ,2 ]
Andreica, Ioana [1 ,2 ]
Baraliakos, Xenofon [1 ,2 ]
Redeker, Imke [1 ,2 ]
Kiltz, Uta [1 ,2 ]
Braun, Juergen [1 ,2 ]
机构
[1] Rheumazentrum Ruhrgebiet, Claudiusstr 45, D-44649 Herne, Germany
[2] Ruhr Univ Bochum, Bochum, Germany
关键词
COVID-19; inflammatory rheumatic diseases; predictors; SARS-CoV-2; vaccination willingness; COVID-19; INFECTIONS; ARTHRITIS;
D O I
10.1177/1759720X221093760
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent surveys in chronic inflammatory rheumatic diseases (CIRD) showed a high degree of vaccine hesitancy. Current knowledge about patients' attitudes toward vaccination against SARS-CoV-2 is limited. Objectives: To assess the willingness of CIRD patients to be vaccinated against SARS-CoV-2 and to identify the influencing factors compared with non-CIRD patients. Methods: In this cross-sectional study, two cohorts of consecutive patients with and without CIRD were recruited in parallel when presenting to our tertiary hospital and asked to answer questions of a structured interview to assess vaccination willingness to SARS-CoV-2 their experience with SARS-CoV-2 and their personal history of infections and vaccinations. Vaccination willingness was assessed using a numerical rating scale (0: fully disagree; 10: fully agree). Arbitrarily defined cut-offs were used to define definite (score >= 7) and probable willingness (score of 5 or 6) to be vaccinated. Factors associated with willingness were assessed using Kendall's tau-b correlation measure and linear regression analysis. Results: A total of 514 CIRD and 100 non-CIRD patients, mean age of 54.7 +/- 12.8 and 55.6 +/- 9.8 years, respectively, were included. Definite and probable willingness to be vaccinated against SARS-CoV-2 was declared by 79.6% and 90.7% versus 76.0% and 85.0% of CIRD and non-CIRD patients, respectively. Only 60% of CIRD patients believed that the vaccines against SARS-CoV-2 were safe, and 42% indicated to be afraid of side effects. Vaccination willingness was significantly correlated with being in a risk group for COVID-19 (tau-b = -0.149), hypertension (tau-b = 0.14), and information about disease prevention (tau-b = 0.19), while a history of infections or immunosuppressive therapy was not. Vaccination willingness was significantly associated with higher education (b = 0.65) and age (b = 0.06). Conclusion: This survey highlights several predictors of relevance for the vaccination willingness of patients with CIRD and controls including appropriate information about its relevance. The good news, however, is that the vast majority of CIRD patients indicated their willingness to be vaccinated. However, there was some uncertainty regarding the safety and efficacy of the vaccines. Since the major influencing factors were education and information about SARS-CoV-2 Vaccine and COVID-19 Disease, patient education should be improved soon.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies
    Doneddu, Pietro Emiliano
    Briani, Chiara
    Cocito, Dario
    Manganelli, Fiore
    Fabrizi, Gian Maria
    Mata, Sabrina
    Mazzeo, Anna
    Fazio, Raffaella
    Benedetti, Luana
    Luigetti, Marco
    Inghilleri, Maurizio
    Ruiu, Elisa
    Siciliano, Gabriele
    Cosentino, Giuseppe
    Marfia, Girolama Alessandra
    Carpo, Marinella
    Filosto, Massimiliano
    Antonini, Giovanni
    Notturno, Francesca
    Sotgiu, Stefano
    Cucurachi, Laura
    Dell'Aquila, Claudia
    Bianchi, Elisa
    Rosso, Tiziana
    Giordano, Andrea
    Fernandes, Marco
    Campagnolo, Marta
    Peci, Erdita
    Spina, Emanuele
    Tagliapietra, Matteo
    Sperti, Martina
    Gentile, Luca
    Strano, Camilla
    Germano, Francesco
    Romozzi, Marina
    Moret, Federica
    Zarbo, Ignazio Roberto
    Viola, Divina Valeria
    Vegezzi, Elisa
    Mataluni, Giorgia
    Cotti-Piccinelli, Stefano
    Leonardi, Luca
    Carta, Alessandra
    Nobile-Orazio, Eduardo
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (07) : 1907 - 1918
  • [22] Long-Term Sequelae of SARS-CoV-2 Infection in Patients with Inflammatory Bowel Diseases Compared to Relatives with SARS-CoV-2 Infection without Inflammatory Bowel Disease and Inflammatory Bowel Disease Patients without SARS-CoV-2: Results of a Retrospective Case-Control Study
    Bierbaum, Benedikt
    von Arnim, Ulrike
    Schmelz, Renate
    Rosania, Rosa
    Walldorf, Jens
    Bierbaum, Michael
    Geissler, Sven
    Haensschen, Markus
    Stallmach, Andreas
    Reuken, Philipp
    Teich, Niels
    [J]. VISCERAL MEDICINE, 2024, : 21 - 31
  • [23] National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD
    Hasseli, Rebecca
    Mueller-Ladner, Ulf
    Schmeiser, Tim
    Hoyer, Bimba F.
    Krause, Andreas
    Lorenz, Hanns-Martin
    Regierer, Anne Constanze
    Richter, Jutta G.
    Strangfeld, Anja
    Voll, Reinhard E.
    Pfeil, Alexander
    Schulze-Koops, Hendrik
    Specker, Christof
    [J]. RMD OPEN, 2020, 6 (02):
  • [24] Addressing Chronic Gynecological Diseases in the SARS-CoV-2 Pandemic
    Tieranu, Maria-Loredana
    Dragoescu, Nicoleta Alice
    Zorila, George-Lucian
    Istrate-Ofiteru, Anca-Maria
    Ramescu, Catalina
    Berbecaru, Elena-Iuliana-Anamaria
    Dragusin, Roxana Cristina
    Nagy, Rodica Daniela
    Capitanescu, Razvan Grigoras
    Iliescu, Dominic-Gabriel
    [J]. MEDICINA-LITHUANIA, 2023, 59 (04):
  • [25] Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
    Bakasis, Athanasios-Dimitrios
    Bitzogli, Kleopatra
    Mouziouras, Dimitrios
    Pouliakis, Abraham
    Roumpoutsou, Maria
    Goules, Andreas V.
    Androutsakos, Theodoros
    [J]. VIRUSES-BASEL, 2022, 14 (02):
  • [26] The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review
    Xie, Yan
    Liu, Yang
    Liu, Yi
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
    Sieiro Santos, Cristiana
    Calleja Antolin, Sara
    Moriano Morales, Clara
    Garcia Herrero, Juan
    Diez Alvarez, Elvira
    Ramos Ortega, Fernando
    Ruiz de Morales, Jose G.
    [J]. RMD OPEN, 2022, 8 (01):
  • [28] 5 reasons to encourage anti-SARS-CoV-2 vaccination in patients with rheumatic diseases
    Motta, Francesca
    Selmi, Carlo
    De Santis, Maria
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (12) : 1241 - 1244
  • [29] Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases
    Patel, Naomi J.
    Cook, Claire
    Vanni, Kathleen
    Fu, Xiaoqing
    Wang, Xiaosong
    Kawano, Yumeko
    Qian, Grace
    Hang, Buuthien
    Srivatsan, Shruthi
    Banasiak, Emily P.
    Kowalski, Emily
    Bade, Katarina
    Zhang, Yuqing
    Sparks, Jeffrey A.
    Wallace, Zachary S. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04) : 565 - 573
  • [30] Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
    Honfi, Daniel
    Gemes, Nikolett
    Szabo, Eniko
    Neuperger, Patricia
    Balog, Jozsef A.
    Nagy, Lajos, I
    Toldi, Gergely
    Puskas, Laszlo G.
    Szebeni, Gabor J.
    Balog, Attila
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)